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Abstract
Left ventricular (LV) thickening can be due to hypertrophy
(concentric, asymmetric, eccentric) or remodelling (concentric
or asymmetric). Pathological thickening may be caused by
pressure overload, volume overload, infiltrative disorders, hy-
pertrophic cardiomyopathy, athlete’s heart or neoplastic infil-
tration. Magnetic resonance imaging (MRI) plays an impor-
tant role in the comprehensive evaluation of LV thickening,
including: establishing diagnosis, determining LV geometry,
establishing aetiology, quantification, identifying prognostic
factors, serial follow-up and treatment response. In this article,
we review the aetiologies and pathophysiology of LV thick-
ening, and demonstrate the comprehensive role of MRI in the
evaluation of LV thickening.
Teaching Points
• MRI plays an important role in the evaluation of LV
thickening.
• LV thickening can be due to either hypertrophy or
remodelling.
• Pathological thickening can be due to pressure/volume over-
load or infiltrative disorders.
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Introduction
Left ventricular (LV) thickening is a commonly encountered
finding in several imaging modalities. LV thickening can be
either due to hypertrophy or remodelling. Pathological LV
thickening may be caused by pressure/volume overload, infil-
trative disorders, hypertrophic cardiomyopathy, athlete’s heart
or neoplastic infiltration (Table 1) [1]. LV hypertrophy (LVH)
is characterized by increased length and width of the myocyte,
as opposed to hyperplasia, which is characterized by genera-
tion of new myocytes. The development of hypertrophy is a
complex process that involves myocardial stress, growth fac-
tors, cytokines, catecholamines and genetic abnormalities [2].
As per Laplace’s law, the load in the myocardium is (pressure
x radius)/ (2 x wall thickness). In pressure overload, hypertro-
phy is caused by increased myosin heavy chain synthesis,
whereas in volume overload, hypertrophy is caused by de-
creased myosin heavy chain degradation. Both these over-
loads also result in reprogramming of several genes, (e.g.,
ANP, ACE, SERCA-2, BBR, M2, etc.), which activate matrix
metalloproteinase (MMPs) and increase the synthesis of col-
lagen 1 resulting in fibrosis [3].
Regardless of the aetiology, LV thickening is an adverse prog-
nostic determinant and requires treatment [1]. LV thickening is
associated with higher risk of cardiovascular morbidity andmor-
tality, independent of other traditional risk factors [4–6]. There is
variability in these outcomes depending on the aetiology, LV
geometry and ethnicity [1]. Regression of LVH has been shown
to be associated with decreased risk and improved outcomes [7].
Imaging plays a vital role in the diagnosis and management of
LV thickening. In this article, we review the comprehensive role
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ofMRI in the evaluation of LV thickening and discuss the utility
of MRI in several aetiologies of LV thickening.
Imaging of left ventricular thickening
Several imaging modalities are available and utilized in the
evaluation of LV thickening, including echocardiography,
computed tomography (CT) and MRI, each with their own
advantages and disadvantages.
Echocardiography
Echocardiography is the most commonly used imaging mo-
dality in the evaluation of LV thickening. LV thickness and
mass is reliably measured using the M-mode [8]. Systolic and
diastolic functions are quantified using real time cine imaging.
Although 2D echocardiography has been shown to be less
accurate and reliable than MRI in the evaluation of the LV
mass [9], 3D echocardiography has good accuracy and repro-
ducibility [1]. Doppler technique is used to evaluate valvular
and vascular lesions. Limitations of echocardiography include
poor acoustic windows, attenuation and operator dependence
[1].
Computed tomography
CT is also occasionally used to evaluate LV thickening, par-
ticularly in patients with contraindications for MRI. CT can
outperform conventional echocardiography in diagnosing and
quantifying the amount of LVH [10]. However, CT has been
shown to overestimate the LV volume [11] and the reliability
of ejection fraction is variable [12]. CT is also associated with
ionizing radiation, potentially nephrotoxic contrast media and
lower temporal resolution [13].
MRI
MRI is the most valuable imaging modality in the evaluation
of LV thickening and enables comprehensive evaluation of
LV thickening, including establishing diagnosis of LV thick-
ening, determining LV geometry, establishing aetiology,
quantification, identifying prognostic factors, serial follow-
up and assessment of treatment response. In certain instances,
particularly with suboptimal echocardiography, MRI is used
in establishing the diagnosis of LV thickening. MRI can ex-
quisitely demonstrate the specific LV geometric pattern,
which has therapeutic and prognostic implications (see be-
low). The tissue characterization capabilities of MRI help in
establishing a specific aetiology of LV thickening, which is
essential for determining the appropriate treatment strategy.
MRI is considered the gold standard in quantification of LV
mass as well as volumes and function due to its high accuracy
and reproducibility [1]. This makes MRI ideal for serial mea-
surements of LV mass in clinical scenarios as well as research
trials to assess treatment response. MRI provides prognostic
information based on mass, volumes, function, and fibrosis.
MRI can evaluate other structures, including vasculature and
valves [14]. Several MRI sequences are used in the evaluation
of LV thickening. ECG-gated steady-state free precession
(SSFP) cine sequence is used in morphological evaluation of
the LV thickening as well as qualitative evaluation of ventric-
ular function. LV mass, volumes and function can also be
quantified from a stack of short axis slices by drawing endo-
cardial and epicardial contours, both in the end-diastolic and
end-systolic phases. Regional myocardial function can be ac-
curately evaluated using several deformation techniques such
as feature tracking, myocardial tagging, strain-encoded MRI
(SENC) and displacement encoding with stimulated echoes
(DENSE) [15]. Some of these techniques such as myocardial
tagging require dedicated post processing software and addi-
tional time, which has precluded widespread clinical adoption
of such techniques. Velocity-encoded phase-contrast (PC) se-
quence is used in the quantification of valvular lesions (steno-
sis, regurgitation), other obstructive lesions (coarctation) and
shunts [16]. T2-weighted sequences (STIR, SSFP) are used in
the evaluation of myocardial oedema. Post-contrast dynamic
first pass perfusion imaging can identify perfusion defects
(e.g., aortic stenosis, hypertrophic cardiomyopathy) [17].
Late gadolinium enhancement (LGE) sequences are used to
detect scar/fibrosis, which helps in establishing aetiology of
LV thickening as well as determining prognosis. T1 mapping
sequences, both pre and post contrast, quantify the T1 values
as well as extracellular volume (ECV), which is more sensitive
in the detection of diffuse fibrosis than LGE. Additionally, T1
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mapping can identify deposits of amyloid, lipid and iron
[18–20]. MR angiography (MRA) is useful in the evaluation
of vascular abnormalities such as coarctation and renal arterial
stenosis. The 4D flow sequences are useful in the assessment
of flow characteristics such as direction and vortices, which
may have a potential future clinical role.
MRI parameters in LV thickening
On MRI, several measurements are utilized to quantify and
characterize LV thickening. LV wall-thickness (LVWT)
measured in an end-diastolic cine image is the most common-
ly used measurement. Normal LV myocardial thickness
is < 11 mm. Myocardial thickening is considered mild if it
measures 11–13 mm, moderate if it measures 14–15 mm
and severe if it measures > 15 mm. LV mass (LVM) is quan-
tified from end-diastolic phase images of short axis cine SSFP
stack by drawing endocardial and epicardial contours. Using
the modified Simpson’s rule, the myocardial volume is obtain-
ed and multiplying this by myocardial density (1.05 g/ml)
gives the myocardial mass. An absolute mass > 184 g in males
and 144 g in females, BMI-indexed mass > 91 g/m2 in males
and > 77 g/m2 in females and height-indexed mass of > 83 g/m
in males and > 69 g/m in females is considered LV thickening
[1, 21, 22]. The height indexed mass is more reliable in obese
patients, and also has been shown to correlate better with
adverse cardiovascular events and mortality [23]. Other pa-
rameters that are crucial in classifying LV thickening are –
Relative wall mass (RWM), which is the ratio of LVM/
LVEDV (end-diastolic volume), normally < 1.16 (Fig. 1);
and Septal/lateral wall thickness, which is the ratio of thick-
ness of septal and lateral segments. This ratio is normally 1,
but is abnormal in patients with asymmetric hypertrophy or
remodelling.
Geometrical patterns of LV thickening
There are five different geometric patterns of LV thickening
that can be exquisitely demonstrated using MRI, namely con-
centric hypertrophy, asymmetric hypertrophy, eccentric hy-
pertrophy, concentric remodelling and asymmetric remodel-
ling (Table 2). Broadly, the hypertrophic geometries are asso-
ciated with increased LWM, while the remodelling geometries
are associated with normal LWM (Fig. 1). Concentric
hypertrophy is characterized by increased LVWT, LVWM
and RWM, but with normal septal/lateral wall ratio. LV vol-
ume is normal or increased and EF is normal or decreased.
This pattern is seen in pressure overload as well as infiltrative
cardiomyopathies. Asymmetric hypertrophy is character-
ized by increased LVWT, LVWM, and RWM, but with an
increased septal/lateral wall ratio. LV volume can be normal
or decreased and EF can be normal or increased. Eccentric
hypertrophy is characterized by increased LVWT and
LVWM, but the RWM is subnormal (<1.16) due to increased
LV volume and the septal/lateral ratio is normal. EF is normal
or decreased. Athlete’s heart is classic example of eccentric
hypertrophy presenting with a normal EF. Concentric
remodelling is characterized by normal LVWT and LVWM,
but the RWM is high due to low LV volume. Septal/lateral
ratio and EF are normal. Asymmetric remodelling is charac-
terized by normal LVWT and LVWM, but the RWM is high
and EF is normal. Unlike concentric remodelling the septal/
lateral ratio is elevated. Concentric hypertrophy, eccentric hy-
pertrophy and concentric remodelling are all associated with
adverse events, with the highest risk seen in concentric hyper-
trophy [24].
Etiologies of LV thickening
The several aetiologies of LV thickening are discussed in
Table 2. A flow chart to distinguish these entities is shown
in Fig. 2. The comprehensive role of MRI in the evaluation of
LV thickening is summarized in Table 3. The most common
aetiologies are discussed in detail below.
Pressure overload
HT
Systemic hypertension (HT) can either be primary or second-
ary to lesions such as renal artery stenosis, adrenal tumours or
coarctation. It has a prevalence of 20–30% [1] with LVH seen
in 30% of HT patients. LVH in HT is predominantly of a
concentric hypertrophic pattern (Fig. 3a, b) [1] and HT is the
most common cause of concentric LVH. Eccentric hypertro-
phy, concentric remodelling or a normal morphology can also
be seen in HT [25]. The EF is preserved, and there is no
systolic anterior motion of mitral valve (SAM) or LVOT ob-
struction. Left atrial enlargement and diastolic dysfunction
may be present, both of which have prognostic value [1].
LV dilation and systolic dysfunction may be seen in advanced
cases with ventricular failure. Myocardial tagging shows de-
pressed circumferential strain, most prominently in the septum
[1]. No perfusion defect is identified per se, but may be seen
due to associated coronary artery disease. LGEmay be seen in
20-45% due to supply–demand mismatch, coronary microan-
giopathy or diffuse interstitial fibrosis [1, 26]. LGE is seen in a
mid-myocardial distribution either in the basal septal or
inferolateral segments [1]. T1- mapping shows diffuse fibro-
sis, more common in eccentric LVH and is associated with
systolic impairment, whereas concentric remodelling is asso-
ciated only with abnormal aortic function [25]. Vascular
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changes of HT seen in MRI include atheroma, ulcer, intramu-
ral hematoma, dissection and occlusive disease. These can be
visualized in sequences such as high-resolution black-blood
T1 and T2-weighted fast spin-echo as well as contrast-
enhanced 3dMRA sequences. MRI is valuable in establishing
the aetiology of secondary hypertension, such as renal arterial
stenosis/coarctation with MR angiography and adrenal
adenoma/pheochromocytoma (Fig. 3c) with multi-sequence
MRI. MRI can be used to follow up response to therapy with
decrease of LVH.
A diagnostic dilemma is to distinguish concentric hyper-
trophy due to HT from a concentric type of hypertrophic car-
diomyopathy (HCM). On MRI, HT patients have normal or
reduced EF, increased chamber volumes and occasional fibro-
sis, while HCM patients have normal or increased EF, normal
chamber volumes and higher incidence of focal/diffuse
Fig. 1 Illustration showing the various types of left ventricular
thickening. In a normal heart, the LV wall thickness, septal/lateral wall
ratio, LV mass, LV volume, relative wall mass and ejection fraction are
normal; in concentric hypertrophy, the wall thickness, LV mass and rel-
ative wall mass are increased.While septal/lateral wall ratio is normal, the
LV volume is normal or increased and ejection fraction is normal or
decreased; in asymmetric hypertrophy, the wall thickness, LV mass and
relative wall mass are increased, but the septal/lateral wall ratio is
increased. In eccentric hypertrophy, the wall thickness and septal/lateral
wall ratio are normal, but LV mass and LV volume are increased, while
ejection fraction and relative wall mass are decreased. In concentric re-
modelling, the relative wall mass is increased, the LV volume is de-
creased, but septal/lateral wall ratio, wall thickness, LV mass and ejection
fraction are normal. In asymmetric remodelling, the relative wall mass is
increased and LV volume is decreased. While septal/lateral wall ratio is
increased, wall thickness, LV mass and EF are normal
Table 2 Types of LV thickening and their distinguishing characteristics
Wall thickness Septal/lateral
wall ratio
LV mass LV volume Relative wall mass
(LVM/EDV)
Ejection fraction
Normal Normal Normal Normal Normal Normal Normal
Concentric remodeling Normal Normal Normal Decreased Increased Normal
Asymmetric remodeling Normal Increased Normal Decreased Increased Normal
Concentric Hypertrophy Increased Normal Increased Normal/Increased Increased Normal/decreased
Eccentric hypertrophy Normal Normal Increased Increased Normal/subnormal Decreased
Asymmetric hypertrophy Increased Increased Increased Normal/decreased Increased Normal/increased
Infiltrative disease Increased Normal Increased Normal/decreased Increased Decreased/normal
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fibrosis. Although not widely available, strain imaging can
help in distinguishing these entities, since HT patients have
high wall stress and lower anteroseptal systolic strains, while
HCM patients have decreased wall stress and longitudinal
strain [2].
Aortic stenosis
Aortic stenosis (AS) is characterized by narrowing of the aor-
tic valve, most commonly due to age related sclerosis, con-
genital bicuspid valve and rheumatic fever. It has a prevalence
of 3- 5%. On MRI, the aortic leaflets are thickened and have
low signal due to fibrosis/calcification. There is restricted
opening of the valve leaflets in systole. The valve narrowing
can be quantified by planimetry in dedicated short-axis views
through the aortic valve (Fig. 4a). A dark dephasing jet is seen
through the aortic valve in systole (Fig. 4b). The velocity of
stenosis can be quantified using PC images obtained either
perpendicular or parallel to the jet. The pressure gradient is
derived by using the modified Bernoulli equation (ΔP = 4v2)
and the stenosis is graded as shown in Table 4 [27]. The aortic
valve morphology in AS is variable, and can be trileaflet,
bicuspid, unicuspid (Fig. 4c) or quadricuspid, best evaluated
in cine SSFP or gradient-echo images. Compensatory concen-
tric LVH is seen in 52% of AS, which reduces the wall stress
and maintains the cardiac output. Eventually, the left ventricle
fails.
Although concentric LVH is the most common type, asym-
metric hypertrophy, concentric remodelling, asymmetric re-
modelling, normal geometry and decompensation are also
seen in AS [22]. There is no correlation between the severity
of valve narrowing and extent of LVH [22]. Asymmetrical
thickening is seen in 22% of AS, involving the basal and
mid septum, which makes this indistinguishable from HCM
[22]. Longitudinal strain may be diminished in early stages. In
late stages, the EF is diminished along with LV dilation. Wall
stress and diminished perfusion is seen in later stages due to
ischemia. LGE may be seen due to fibrosis, likely due to
myocardial ischemia caused by higher demand of LVH and
high systolic pressure, and decreased myocardial perfusion
due to lower aortic pressure, lower diastolic duration and ab-
sence of coronary vasodilation [28, 29]. LGE is most com-
monly seen in the basal segments, typically in a diffuse sub-
endocardial distribution, but occasionally in a mid-myocardial
distribution [30, 31]. LGE is associated with severe hypertro-
phy and adverse prognosis. MRI is also useful in the evalua-
tion of patients being considered for transcutaneous aortic
valve implantation (TAVI), especially in patients with contra-
indication for CT, by measuring the annulus, sinus of
Valsalva, annulus to coronary ostial distance, fluoroscopic an-
gulation plane and also the dimension and orientation of the
peripheral access vessels [32].
Aortic coarctation
Aortic coarctation is discrete narrowing of the aorta, usually
seen beyond the level of ductus arteriosus, but may also be
seen proximal to it. More extensive areas of involvement re-
sult in hypoplasia. Coarctation has a prevalence of 0.01 to
0.03% and is seen in 0.2% of hypertensive adult patients
[33]. Coarctation produces concentric LVH due to pressure
overload. Hypertension is seen either due to mechanical ob-
struction, activation of the renin-angiotensin system, neural
reasons and/or Goldblatt type phenomenon [1]. On MRI, the
Fig. 2 Flow chart showing the
differentiation of various causes
of LV thickening
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Table 3 Summary of the role of
MRI in LV thickening Disease Role of MRI
General Establishing the presence of hypertrophy
Characterizing the geometry




Systemic hypertension Secondary causes of hypertension- renovascular, adrenal lesion
Aortic stenosis Planimetry- Aortic valve area
Phase contrast- Quantification of stenosis
Fibrosis
Evaluation for TAVI




Subaortic membrane Membrane- Location, size
Quantification of obstruction
Aortic/mitral regurgitation Quantification of regurgitation
Volume quantification
Dilated cardiomyopathy Quantification of volumes
Fibrosis
Amyloidosis T1 kinetics and T1 mapping- Diagnosis and prognosis
Late gadolinium enhancement
Danon disease Fibrosis
Hypertrophic cardiomyopathy Pattern of HCM
Quantification of obstruction
Mitral valve abnormalities- SAM, elongated anterior leaflet
Papillary muscle abnormalities
Fibrosis
Athlete’s heart Quantification of volumes
Response to deconditioning
Anderson Fabry disease T1 mapping allows detection of fibrosis and lipid deposition
Iron overload cardiomyopathy Myocardial iron quantification
Fig. 3 a Short axis cine-SSFP image in a patient with hypertension
shows severe concentric LV hypertrophy with maximal thickness of
2.2 cm in the mid septum in end diastole. b 4-chamber cine SSFP image
in another patient with HT shows severe concentric LV hypertrophy. c
Coronal T1-weighted image through the upper abdomen after gadolinium
administration shows an intensely enhancing mass in the upper abdo-
men (arrow), consistent with a pheochromocytoma
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coarctation and collateral vessels are evaluated and quantified
using cine-SSFP or MR angiographic images (Fig. 5a). MRI
can assess the presence and direction of flow in collaterals.
The flow velocity, flow volume and pressure gradients at the
coarctation site can be measured using a velocity-encoded PC
sequence (Fig. 5b). Presence of higher flow in the distal seg-
ment of descending thoracic aorta compared to the proximal
segment is an indicator of hemodynamically significant ob-
struction due to filling of the distal aorta by collateral vessels.
LVH is seen in 20–40% of coarctat ion [33, 34].
Subendocardial ischemia and abnormal arterial stiffness are
also seen [1]. Associations of coarctation include bicuspid
aortic valve, ventricular septal defect (VSD), hypoplastic left
heart and subaortic stenosis, all of which can be evaluated
using MRI. MRI is used for preoperative/interventional plan-
ning and post-treatment assessment of complications.
Subaortic membrane
The subaortic membrane is a discrete fibrous membrane, mus-
cular narrowing or a combination of both. It usually involves
the LV outflow tract (LVOT), but may also involve the sep-
tum, anterior mitral leaflet or the aortic valve. Common as-
sociations of subaortic membrane include bicuspid aortic
valve, AV canal, Shone’s complex, tunnel subaortic stenosis
and VSD. OnMRI, focal discrete narrowing of the LVOT by a
membrane is identified (Fig. 6) in cine SSFP and 3D whole
heart SSFP images. Flow acceleration and dephasing is also
identified (Fig. 6) in cine images, which can be quantified by
using PC images. A peak gradient > 50 mm Hg is considered
to be severe obstruction. Concentric LVH is present due to
pressure overload and subendocardial ischemia may be seen.
Complications include infective endocarditis and aortic regur-
gitation due to structural valvular damage. Treatment is with
surgical resection when there is either hemodynamically sig-
nificant obstruction or aortic valvular involvement [35].
Volume overload
Volume overload conditions such as long-standing aortic or
mitral regurgitation and dilated cardiomyopathy lead to com-
plex forms of adaptation resulting in eccentric LV hypertro-
phy. The LVWT and LVWM are increased, but the RWM is
lower than normal due to ventricular dilation. MRI can quan-
tify the regurgitation as well as its secondary effects on the
ventricle including abnormal chamber size and function. In
dilated cardiomyopathy, the LV is dilated and there is global
systolic dysfunction. A nonischemic pattern of LGE may be
seen, in a mid-myocardial or subepicardial distribution
Fig. 4 a Short axis cine SSFP image through the aortic valve shows
thickening of the valve leaflets (arrow) and restricted systolic opening.
The valve area was measured to be 0.5 cm2, consistent with severe aortic
stenosis. b 3-chamber cine SSFP sequence in the same patient shows
restricted systolic opening of the aortic valve and flow acceleration
through the aortic valve (straight arrow), consistent with aortic stenosis.
Concentric LV hypertrophy is also seen (curved arrow). c Short axis cine
SSFP image through the aortic valve shows a unicuspid aortic valve with
thickened leaflets (arrows) and restricted opening consistent with aortic
stenosis
Table 4 Grades of aortic stenosis [27]
Peak velocity (m/s) Mean gradient Valve area Indexed valve area Velocity ratio
Mild 2.6-2.9 <20a (<30b) mm Hg <1.5 cm2 0.85 cm2/m2 >0.5
Moderate 3.0-4.0 20-40a (30–50 b) mm Hg 1-1.5 cm2 0.60-0.85 cm2/m2 0.25-0.5
Severe >4.0 >40a (50b) mm Hg <1 cm2 <0.6 cm2/m2 <0.25
a AHA/ACC guidelines
b ESC guidelines
Insights Imaging (2017) 8:279–293 285
depending on the underlying aetiology [36]. A linear mid-
myocardial pattern has been described in idiopathic dilated
cardiomyopathy [36].
Infiltrative cardiomyopathies
Infiltrative cardiomyopathies are characterized by the deposi-
tion of abnormal substances in the myocardium resulting in
diminished ventricular filling. Some of these entities cause LV
thickening, whereas other entities predominantly manifest as
chamber dilation and wall thinning but occasionallymayman-
ifest with wall thickening/remodelling. The former category
includes cardiac amyloidosis, Fabry’s disease, Danon disease,
eosinophilic heart disease, Friedreich ataxia, oxalosis and
mucopolysaccaridoses, while the latter category includes sar-
coidosis and iron overload cardiomyopathy [37].
Cardiac amyloidosis
Cardiac amyloidosis is characterized by the deposition of ß-
pleated amyloid proteins, with an estimated prevalence of
0.001%. In the AL type, cardiac involvement is seen in 33%;
in the AA type, cardiac involvement is unusual and in TTR-
type; there are specific gene mutations [38]. On MRI, concen-
tric LV thickening is seen, along with thickening of the RV,
atria, interatrial septum and valves (Fig. 7a). Biatrial dilation
and decreased LV volumes are also present. Longitudinal strain
is decreased in the early stages and eventually EF is also de-
creased. There is no SAM or LVOT obstruction. Perfusion is
usually normal, but a subendocardial defect may be seen. Due
to interstitial expansion from amyloid deposition, LGE is seen
in 69-97% of all cardiac amyloidosis patients, 100% of TTR
type and 64% of AL type [38]. LGE is usually seen in a global
transmural or subendocardial pattern (83%) (Fig. 7b), but oc-
casionally may be focal and patchy (6%). In 8% of patients, a
suboptimal myocardial nulling (8%) may be the only finding.
LGE is seen in MRI in 47% of confirmed cardiac amyloidosis
patients without echocardiographic findings [39]. LGE is asso-
ciated with NYHA functional class, ECG voltage, LVM index,
RV wall thickness, troponin T and BNP levels [37]. Alteration
in T1 kinetics can be demonstrated in the T1-scout images,
with nulling of the myocardium occurring at the same time or
even before nulling of the blood pool (Fig. 7c) (which is the
reverse of the normal pattern where the normal myocardium
always nulls after the blood pool). At 2 minutes post contrast, a
T1 difference between subepicardium and subendocardium
of < 23 milliseconds (ms) is a predictor of mortality with 85%
accuracy [38]. Native T1 mapping shows elevated T1 values,
which is an early indicator and direct marker of cardiac amyloid
[40]. Higher ECV has been shown with post contrast T1 map-
ping, which directly correlates with LGE, indexed LVmass and
other clinical adverse prognostic factors [41].
Fig. 5 a Sagittal volume
rendered 3D image in a patient
with concentric LV thickening
shows severe coarctation of the
aortic arch (straight arrow) and
multiple collateral vessels(curved
arrows). b Velocity encoded
phase contrast image in the
sagittal plane in another patient
shows flow acceleration through
the aortic arch at the site of
coarctation, which was quantified
and the pressure gradient
was estimated to be 20 mm Hg
Fig. 6 3-chamber cine SSFP image shows concentric LV thickening.
There is flow acceleration in the LVOT below the level of the aortic
valve (straight arrow). There is a linear discrete membrane at the LVOT
(curved arrow), which is responsible for the flow acceleration, consistent
with a subaortic membrane
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Anderson-Fabry’s disease
Anderson-Fabry’s disease is an X-linked storage disorder
characterized by the accumulation of glycosphingolipid due
to a deficiency ofα- galactosidase enzyme. In the early stages,
there is concentric LV thickening, prominent papillary mus-
cles, preserved EF and diastolic dysfunction, which then pro-
gresses to intramural replacement fibrosis, regional wall mo-
tion abnormalities [42] and arrhythmias. On MRI, LV thick-
ening is present, usually concentric but may be asymmetric.
Fabry’s disease accounts for 3% of all LVH [43]. Fabry’s
disease has been shown to be the aetiology in 6–12% of pa-
tients presenting with suspected symmetric HCM [44]. LGE is
seen in up to 50% of patients with Fabry’s disease due to
cardiac infiltration [45]. LGE in Fabry’s disease is typically
seen in the basal inferolateral wall in a mid-myocardial or
subepicardial pattern (Fig. 8). However, in HCM, LGE is seen
in hypertrophied as well as non-hypertrophied segments, usu-
ally in a mid-myocardial distribution or at RV insertion points
[45]. LGE is associated with poor prognosis. Native T1 values
are low in Fabry’s disease due to presence of lipids, whereas in
HCM it is high due to fibrosis. Elevated T2, RV involvement,
valve thickening/dysfunction and decreased longitudinal sys-
tolic motion have also been reported in Fabry’s disease.
Danon disease
Danon disease is an X-linked dominant lysosomal storage dis-
order characterized bymutation of lysosomal associated protein-
2 (LAMP2). Cardiac manifestation of Danon disease includes
concentric LV thickening, cardiac failure and Wolff-Parkinson-
White syndrome. Other features are myopathy, elevated creatine
kinase, eye abnormalities and mental retardation. On MRI, con-
centric LV thickening is present. Danon disease has been
confirmed as the correct diagnosis in 4% of patients initially
diagnosed as HCM [46]. Myocardial oedema and perfusion
defect are occasionally seen. LGE is seen in a non-ischemic
pattern in a mid-myocardial distribution [47] (Fig. 9), but occa-
sionally subendocardial and transmural distribution may be seen
[48]. There is often sparing of the septum between the RV in-
sertion points [49]. Involvement of the heart is associated with
poor prognosis. Due to the risk of sudden cardiac death, implant-
able cardioverter defibrillator (ICD) placement or cardiac trans-
plantation are performed.
Eosinophilic endocarditis
Eosinophilic endocarditis (endomyocardial fibrosis, Löeffler
endomyocarditis) is a part of the spectrum of hyperesosinophilic
Fig. 7 a 4-chamber SSFP image in a patient with cardiac amyloidosis
shows concentric LV thickening (straight arrow). There is also thickening
of the interatrial septum (curved arrow). b Post contrast T1-w inversion
recovery gradient echo image shows diffuse sub-endocardial to mid
myocardial LGE of the ventricles (straight arrow), interatrial septum
(curved arrow) and the atrial walls (arrowhead). c Short-axis TI scout
(Look Locker sequence image) at the level of mid-ventricular septum in
a patient with cardiac amyloidosis. At an inversion time of 150 millisec-
onds, both the blood pool (LV) andmyocardium (M) are dark. This is due
to diffuse myocardial infiltration with amyloid, which takes up gadolin-
ium and results in T1 shortening
Fig. 8 Short-axis post contrast T1-w inversion recovery gradient echo
MRI sequence shows patchy mid myocardial LGE in the basal lateral
(straight arrow) in a patient with Anderson Fabry’s disease
Insights Imaging (2017) 8:279–293 287
syndrome, which is characterized by elevated eosinophils >
1500/ μL > 6 months and organ dysfunction. The heart is the
most commonly involved organ and cardiac involvement is as-
sociated with adverse prognosis. There are three stages of car-
diac involvement. In the acute necrotic stage, there is eosinophil-
ic infiltration of the endocardium and myocardium. This is
followed by the thrombotic-necrotic stage, which is associated
with ventricular damage. In the late fibrotic stage, there is diffuse
fibrous tissue lining the endocardium often extending from the
LVOT to the apex. On MRI, there is thickening of the LVapex,
which can be confused with apical HCM. A high T2 signal may
be seen in the apical endocardium. Diffuse subendocardial per-
fusion defect may be present. On LGE, a triple layered pattern of
enhancement is a characteristic finding of eosinophilic endocar-
ditis. This includes an inner dark layer due to non-enhancing
thrombus, a middle bright layer due to LGE from fibrous tissue
and an outer dark layer of normally nulled myocardium
(Fig. 10). Patchy intramyocardial LGE may also be present
[50, 51]. Associated wall motion abnormalities and dilated left
atrium may also be seen. Treatment is surgical resection of the
fibrous tissue.
Iron overload cardiomyopathy
Iron overload cardiomyopathy is characterized by excess
myocardial iron deposition, secondary to hemochromatosis,
sickle cell disease, thalassemia, multiple transfusions or in-
creased gastrointestinal (GI) absorption of iron [52]. It has
an estimated prevalence of 0.0001%. There are two pheno-
types of iron overload cardiomyopathy, the restrictive type
with preserved EF, diastolic dysfunction, LA/RV dilation
and pulmonary hypertension; and the dilated type with LV
remodelling, chamber dilation and decreased EF [53].
Eccentric hypertrophy, high EF and high cardiac output may
also be seen [53]. Iron overload cardiomyopathy can result in
ventricular failure, arrhythmia and mortality [52]. Hence, it is
the most important determinant of survival in patients with
thalassemia or multiple transfusions. It is imperative to make
the diagnosis of iron overload cardiomyopathy prior to the
development of overt cardiac failure, since early initiation of
chelation therapy can improve the outcome and reduce ad-
verse events [52]. On MRI, multi-echo gradient echo images
are obtained in the same slice at different TE values, and the
mean myocardial signal intensity at each TE level is measured
(Fig. 11). A curve fit is used to obtain myocardial T2. Normal
myocardial T2* is 33 ± 6.5 milliseconds. Myocardial iron de-
position is diagnosed when T2* is < 20 milliseconds and is
considered severe, when T2* is < 10 milliseconds [54].
Sarcoidosis
Sarcoidosis is a systemic disorder characterized by the pres-
ence of non-caseating granulomas. Cardiac involvement is
seen in 5–20% of patients with sarcoidosis. In the acute stage,
diffuse myocardial thickening may be seen due to diffuse in-
filtration. Regional wall motion abnormalities, myocardial oe-
dema and LGE are also seen. LGE is seen in a mid-myocardial
or subepicardial distribution. On STIR, confluent granulomas
may be seen with a central low signal of fibrous tissue and a
peripheral rim of high signal with a nodular component, more
common in the basal septum than the lateral wall. In the chron-
ic stage, patchy areas of mid-myocardial to subepicardial LGE
may be seen with associated normal or thinned myocardium
(Fig. 12) [55]. No oedema is seen in the chronic stage.
Uncommon conditions
Myocardial oxalosis is characterized by the deposition of
oxalic acid crystals in the heart due to its higher production.
Fig. 10 3-chamber post contrast T1-w inversion recovery image shows a
triple layered pattern of enhancement with an inner layer of dark
thrombus (arrowhead), middle layer of LGE due to enhancing fibrous
tissue (straight arrow) and an outer layer of dark normal myocardium
(curved arrow)
Fig. 9 Short-axis post-contrast T1-w inversion recovery gradient echo
image shows patchy mid myocardial LGE (arrows) of severely thickened
myocardium in a patient with Danon disease
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Clinical presentation includes LVH, heart block and conduc-
tion abnormalities. On MRI, there is concentric left and right
ventricular thickening. Diastolic dysfunction may be seen.
Friedreich ataxia is characterized by mitochondrial ion accu-
mulation, with cardiomyopathy seen in 63%. On MRI,
concentric or asymmetric LVH is seen, without evidence of
LVOT obstruction. Diastolic dysfunction and fibrosis may be
seen [37].Mucopolysaccharidoses can present with variable
MRI appearance depending on the phenotype, including
asymmetrical septal thickening, mitral and or aortic valve
stenosis/insufficiency with normal EF [37]. In obesity, LVH
with high LVM, LVEDVand RWM is seen, with preserved EF
[56] which correlates with the body mass. LVH with higher
LVM with normal EF is also seen in DM Type II, correlating
with BMI and HbA1c [57].
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is characterized by
myocardial hypertrophy without an underlying cause such as
HT or AS. It is caused by sarcomeric gene mutations and has
variable phenotypic expression. It has a prevalence of 0.2%,
and LVH is seen in 60% of these patients [1]. The most com-
mon pattern of HCM is the asymmetrical hypertrophy, which
typically involves the basal ventricular septum (Fig. 13a), but
occasionally may involve the apical region (Yamaguchi type)
(Fig. 13b), mid-ventricular region or even the lateral wall.
Spiral and mass-like types (Fig. 13c) have also been de-
scribed. The concentric type of HCM is rarely seen. On
Fig. 11 Short-axis multi-echo gradient echo T2 weighted images obtained at different TEs, shows that the myocardium gets progressively darker with
increasing TEs, with complete darkness at TE of 14.2 milliseconds, indicating significant iron deposition
Fig. 12 Short-axis post-contrast T1-w inversion recovery gradient echo
image shows mild concentric LV thickening and patchy areas of mid
myocardial and subepicardial LGE (arrows) in a patient with cardiac
sarcoidosis
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MRI, there is asymmetric hypertrophy, with a septal/lateral
wall > 1. EF is either normal or hyperdynamic. Ventricular
chamber size is normal but may be dilated in the end stages.
In the obstructive type (HOCM), there is flow acceleration in
the LVOT due to narrowing, which results in systolic
dephasing. This can be quantified using velocity encoded
PC imaging. SAM augments this obstruction and also results
in eccentric posteriorly mitral regurgitation and left atrial en-
largement. MRI can also help in evaluating papillary muscle
abnormalities such as abnormal insertion, position and mobil-
ity which can augment the obstruction or may be the only
cause of obstruction. Occasionally these abnormalities are
seen without significant hypertrophy. While the classical
HCMmay need surgical myectomy or septal alcohol ablation,
papillary muscle abnormalities require specific surgeries such
as reimplantation of papillary muscles [58]. Mitral valve ab-
normalities, such as elongation, can also be seen in MRI [59],
and these require mitral valve surgery. Stress perfusion defects
may be seen. LGE is seen in 40–80% of HCM patients, either
due to myocyte disarray, dysplasia of intramyocardial arteri-
oles, interstitial fibrosis, or other types of fibrosis (plexiform,
pericellular, perivascular, or substitution) [60]. LGE is typical-
ly patchy and seen in a mid-myocardial distribution, both in
hypertrophied and non-hypertrophied areas, and also at RV
insertion points (Fig. 13d). Detection and quantification of
LGE is the most significant contribution of MRI in HCM,
since the presence of LGE has been shown to be associated
with adverse cardiovascular events including arrhythmias and
sudden cardiac death, often warranting ICD placement
[60–62]. LGE often underestimates the amount of fibrosis in
HCM, since the fibrosis is diffuse, and; hence, establishing a
normal myocardium to determine a threshold is challenging.
T1 mapping is more sensitive in detection of diffuse fibrosis,
with higher native T1 values and elevated ECV described in
HCM. There is no correlation between LGE and T1 values,
indicating that diffuse and regional fibrosis in HCM may be
different entities [63].
Athlete’s heart
Athlete’s heart is a physiological hypertrophy seen as an adap-
tive response to the altered loading conditions of prolonged
and intensive training. This has been reported in an estimated
2% of athletes [64]. At a cellular level, the normal structural
organization and function are preserved, and the signalling
pathway for this response is also distinct (IGF-1/IGF-1R/Akt
axis) from pathological hypertrophy [65]. The LV geometry is
variable- concentric hypertrophy in strength-trained athletes
due to pressure overload; eccentric hypertrophy in
endurance-trained athletes due to volume overload; and a
mixed pattern of concentric-eccentric hypertrophy in others.
MRI shows hypertrophy, which may be concentric, eccen-
tric or mixed concentric-eccentric (Fig. 14). Distinguishing
Fig. 13 a Short-axis SSFP image shows severe asymmetric hypertrophy
of the mid-ventricular septum, while the lateral, anterior and inferior
segments appear to be of normal thickness. b 2-chamber SSFP image
shows severe thickening of the apical LV segments, consistent with
apical variant (Yamaguchi type) of hypertrophic cardiomyopathy. c 3-
chamber cine SSFP image shows extensive mass-like appearance of a
focal hypertrophic cardiomyopathy involving the mid-ventricular
septum (arrow). d Short axis post contrast inversion recovery SSFP
sequences shows patchy, fine mid-myocardial LGE of the
hypertrophied septum, especially at RV insertion points (arrows) that
are consistent with interstitial fibrosis in a pattern that is specific for
hypertrophic cardiomyopathy
Fig. 14 4-chamber cine SSFP image shows mild LV thickening (15mm)
and mild LV dilation (EDV-200 ml; EDVi- 120 ml/m2) with normal
systolic function (EF- 59%). There was no abnormal LGE. This was
diagnosed as athlete’s heart. After cessation of athletic training for three
months, the ventricular measurements returned to normal
290 Insights Imaging (2017) 8:279–293
athlete’s heart from HCM is critical, since missing a diagnosis
of HCM puts the athlete at risk of sudden death and an erro-
neous diagnosis of HCM will disqualify an otherwise eligible
athlete from contact sports [66]. Features that distinguish ath-
lete’s heart from HCM are – the LVWT is < 15 mm in males
and 13mm in females; symmetrical thickening; normal septal/
lateral wall ratio; dilated cavity (but end-diastolic diameter <
6.5 cm), resulting in low RWM of <1.16; diastolic wall-to-
volume ratio < 0.15 mm x m2 x ml [66]; normal systolic func-
tion; normal/high diastolic function; and no LVOT gradient,
SAM or perfusion defect. LGE is typically not seen unlike
HCM; however, some studies have described LGE in12-
50% of athletes [67, 68], with heterogeneous appearance,
more commonly in the septum at the RV insertion site.
Although the exact mechanism is unknown, theories include
repetitive myocardial microtrauma, pulmonary artery pressure
overload with dilated RV, genetic predisposition and silent
myocarditis [68]. There may be proportional enlargement of
the RV and atria. Clinical features that help in diagnosis are:
absence of genetic abnormalities, milder ECG abnormalities
(conduction delays, sinus bradycardia) and a peak oxygen
uptake that is higher than expected for the age, gender and
size. If the diagnosis of athlete’s heart still remains indetermi-
nate after using all the abovementioned criteria, it may be
confirmed by regression of the structural changes following
a period of deconditioning.
Neoplastic infiltration
Diffuse LV thickening may also be seen due to diffuse or
multifocal neoplastic infiltration. This includes neoplasms
such as metastases, lymphoma, leukemia or sarcoma. B cell
lymphoma is the most common type of lymphoma to produce
diffuse myocardial infiltration [69]. Although cardiac leuke-
mic infiltration is present in 37–44% of patients with leuke-
mia, clinically it is seen only in 1% of these patients [70].
While leukemic deposits may not be separately discerned,
lymphomatous and metastatic deposits are often grossly seen.
On black-blood MRI, LV thickening is present, which is more
irregular and has heterogeneous signal intensities compared to
the other causes of LV thickening. The imaging appearance
mimics HCM in non-contrast sequences, but in contrast-
enhanced sequences, heterogeneous enhancement is noted
(Fig. 15). Associated findings such as pericardial effusion
may also be present.
False positive hypertrophy
Occasionally, pseudohypertrophy may be seen due to partial
averaging of normal structures. This may be seen due to a
prominent moderator band, whichmay give a false impression
of septal hypertrophy (Movies 1 and 2).
Summary
MRI plays an important role in the comprehensive evaluation
of patients with LV thickening. The unique tissue characteri-
zation capabilities of MRI enable establishing the aetiology of
LV thickening, which is important for selecting the appropri-
ate treatment. The high accuracy and reproducibility of MRI
measured indices such as mass, volumes and function make it
the ideal modality for serial follow-up in clinical scenarios and
trials to evaluate treatment response. In addition, MRI also
provides prognostic information.
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